Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1435)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3390)
  2. Solid Tumor Oncology Division (3390)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (636)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (110)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (702)
  2. Journal of Thoracic Oncology (515)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (781)
  2. Elsevier Inc. (736)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3390)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bleeding in lung cancer patients receiving therapeutic anticoagulation while being treated with VEGF and EGFR inhibitors
    Meeting Abstract

    Fusillo, T. F.; Leader, A.; Mantha, S.; Ajufo, H.; Derkach, A.; Schoenfeld, A.; Singh, R.; Kaplinsky, P.; Zwicker, J. I.
    Blood (2024)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of safety outcomes with MET tyrosine kinase inhibitors (TKIs) in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Taylor, K.; Veillon, R.; Griesinger, F.; Reinmuth, N.; Ghori, V.; Vioix, H.; Clark, A.; Paik, P.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study
    Meeting Abstract

    Johnson, M. L.; Simoes da Rocha, P. F.; Kim, Y. J.; Chen, Y.; Paz-Ares, L. G.; Girard, N.; Hann, C. L.; Nishio, M.; Ahn, M. J.; Qian, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)
    Meeting Abstract

    Rudin, C. M.; Salkeni, M. A.; Gutierrez, M.; Hayashi, H.; Thompson, J.; Arca, M.; Hirose, D.; Singh, J.; Turner, J.; Zhang, Y.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004
    Meeting Abstract

    Cobb, P. W.; Hochmair, M.; Schuler, M. H. H.; Riely, G. J.; Rojas, C. I.; Kim, S. J.; Chen, X.; Lara-Guerra, H.; Felip, E.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
    Meeting Abstract

    Skoulidis, F.; Li, B. T.; Hochmair, M. J.; Govindan, R.; Vincent, M.; Van Der Wekken, A. J.; Reguart Aransay, N.; O'Byrne, K. J.; Girard, N.; Griesinger, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Murray, J. C.; Huang, Q.; Hu, C.; Curran, E.; Wong, C.; Glatz, L.; Wang, T.; Hasan, A.; Villaruz, L.; Schoenfeld, A.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC
    Meeting Abstract

    Krebs, M. G.; Lu, S.; Fan, Y.; Yu, Y.; Drilon, A. E.; Siena, S.; Xue, C.; Bradley, D.; Hu, X.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial
    Meeting Abstract

    Solomon, B. J.; Drilon, A. E.; Wirth, L. J.; Szpurka, A.; Rao, X.; Massey, A. C.; Barker, S.; Wright, J.; Won, H.; Cabanillas, M. E.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
    Meeting Abstract

    Cho, B. C.; Ahn, M. J.; Kim, T. M.; Kim, S. W.; Han, J. Y.; Kim, C.; Shim, B.; Ricordel, C.; Drilon, A. E.; Pujol, J. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save